Skip to main content

Advertisement

Table 2 Prognostic factors for disease-free survival (DFS): univariate analysis

From: Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study

  N 5-Year DFS (%) (95 % CI) HR (95 % CI) p-valuea
Age
  < 35 30 82.6 [68.2–100] 1  
  ≥ 35 726 90.9 [88.5–93.4] 0.5 [0.2–1.3] 0.136
SBR Grade
 1–2 462 93.2 [90.5–95.9] 1  
 3 285 86 [81.4–91] 1.8 [1.1–2.9] 0.0138
Pathological tumor size
 pT1 391 91.2 [87.9–94.5] 1  
 pT2 320 90 [86.2–94] 1.1 [0.7–1.8]  
 pT3-T4 36 88.2 [78–99.8] 1.1 [0.4–3] 0.9514
PVI
 No 558 92.3 [89.7–95] 1  
 Yes 178 85 [79–91.4] 2.3 [1.4–3.7] 0.0007
Hormone receptors
 Negative 208 86.8 [81.6–92.4] 1  
 Positive 526 92.5 [89.9–95.2] 0.7 [0.4–1.1] 0.1059
HER2
 Negative 507 91 [88–94.1] 1  
 Positive 96 95.7 [91–100] 0.6 [0.2–1.6] 0.376
IHC subtypes
 Luminal A 289 95.1 [92.1–98.2] 1  
 Luminal B/HER2-negative 82 80.1 [69.8–92] 4.3 [2–9.1]  
 Luminal B/HER2-positive 58 100 [100–100] 0.7 [0.2–3.3]  
 HER2 37 89 [77.6–100] 1.8 [0.5–6.2]  
 Triple-negative 127 87.6 [80.7–95] 2.6 [1.2–5.5] 0.0006
  1. HR hazard ratio, PVI peritumor vascular invasion
  2. aunadjusted log-rank test